Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer

Kawajiri,Hidemi; Takashima,Tsutomu; Onoda,Naoyoshi; Kashiwagi,Shinichiro; Noda,Satoru; Ishikawa,Tetsurou; Wakasa,Kenichi; Hirakawa,Kosei

doi:10.3892/ol.2012.801

October 2012 Volume 4 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October 2012 Volume 4 Issue 4

Full Size Image

Article

Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer

Authors:
- Hidemi Kawajiri
- Tsutomu Takashima
- Naoyoshi Onoda
- Shinichiro Kashiwagi
- Satoru Noda
- Tetsurou Ishikawa
- Kenichi Wakasa
- Kosei Hirakawa
View Affiliations / Copyright

Affiliations: Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan, Department of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Pages: 612-616
|
Published online on: July 13, 2012

https://doi.org/10.3892/ol.2012.801
Expand metrics +

Abstract

Sequential administration of anthracyclin and taxane for neoadjuvant chemotherapy (NAC) is the standard treatment for operable breast cancer. The pathological complete response (pCR) is a significant predictor of overall survival (OS), regardless of treatment. In this study, the pCR rate was retrospectively examined and compared with the treatment efficacy and the characteristics of pCR patients were analyzed. A total of 54 female patients with operable breast cancer, treated with FEC 100 followed by weekly paclitaxel between December 2005 and May 2009 at the Osaka City University Hospital, Osaka, Japan, were retrospectively reviewed. A total of 21 patients (39%) achieved pCR. The overall response rate was 91%. Only one patient had progressive disease. The pCR rate was significantly higher in those patients with estrogen receptor (ER)- and progesterone receptor (PR)-negative tumors and in those patients who completed the treatment course. An NAC regimen incorporating FEC 100 followed by weekly paclitaxel is effective for treating operable breast cancer.

View Figures

View References

1.	N WolmarkJ WangE MamonasB FisherPreoperative chemotherapy in patients with operative breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18J Natl Cancer Inst Monogr3096102200111773300
2.	JA van der HageCJ van de VeldeJP JulienM Tubiana-HulinC VanderveldenL DuchateauPreoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902J Clin Oncol19422442372001
3.	HD BearS AndersonA BrownNational Surgical Adjuvant Breast and Bowel Project Protocol B-27: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project B-27J Clin Oncol21416541742003
4.	HD BearS AndersonRE SmithSequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27J Clin Oncol2420192027200610.1200/JCO.2005.04.1665
5.	IC HerdersonDA BerryGD DemetriImproved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancerJ Clin Oncol21976983200310.1200/JCO.2003.02.063
6.	EP MamonasJ BryantBC LemberskyPaclitaxel after doxorubicin puls cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28J Clin Oncol2336863896200510.1200/JCO.2005.10.51715897552
7.	H RochéP FumoleauM SpielmannSequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 TrialJ Clin Oncol24566456712006
8.	J BonneterreH RochéP KerbratEpirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trialJ Clin Oncol23268629932005
9.	The Japanese Breast Cancer SocietyGeneral Rules for Clinical and Pathological Recording of Breast Cancer16th editionKanehara Shuppan602008
10.	VA MorrisonAn overview of the management of infection and febrile neutropenia in patients with cancerSupport Cancer Ther28894200510.3816/SCT.2005.n.00218628193
11.	JA SparanoM WangS MartinoWeekly paclitaxel in the adjuvant treatment of breast cancerN Engl J Med35816631671200810.1056/NEJMoa070705618420499
12.	MC GreenAU BuzdarT SmithWeekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeksJ Clin Oncol2359835992200510.1200/JCO.2005.06.23216087943
13.	IC SmithSD HeysAW HutcheonNeoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxelJ Clin Oncol2014561466200210.1200/JCO.20.6.145611896092
14.	A KhanD McNallyPJ TutschkaS BilgramiPaclitaxel-induced acute bilateral pneumonitisAnn Pharmacother311471147419979416383
15.	DF HayesAD ThorLG DresslerHER2 and response to paclitaxel in node-positive breast cancerN Engl J Med35714961506200710.1056/NEJMoa07116717928597
16.	ML CitronDA BerryC CirrincioneRandomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741J Clin Oncol21143114392003
17.	AU BuzdarNK IbrahimD FrancisSignificantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, pacritaxel and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerJ Clin Oncol2336763685200510.1200/JCO.2005.07.032
18.	R GrayS BhattacharyaC BowdenK MillerRL ComisIndependent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancerJ Clin Oncol2712151221200910.1200/JCO.2008.21.663019720913